Project Grant R21CA304643
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $462K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $796,299 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single chromatin fiber multiomic mapping in opioid use disorder brain tissue. The recipient will perform genome-wide profiling of chromatin organization directly from frontal and cingulate cortex nuclei obtained from donors with chronic opioid use disorder. The work charts nucleosomal array organization,...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai a cooperative agreement valued at $749,153 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a phased, randomized, double-blind clinical trial testing transcranial direct current stimulation (tDCS) over the right dorsolateral prefrontal cortex to reduce craving and cue reactivity in patients with opioid use disorder. The study will randomize 60 inpatients with...
- The National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $170,640 on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds development and feasibility testing of TOPMED (Toolkit for Optimal Pain Management in the Emergency Department), a mind-body intervention designed to reduce pain...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Mayo Clinic Jacksonville $2,277,111 on September 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop the PAIN (Pain AI Intervention) platform, a wearable sensor-based artificial intelligence system for at-home continuous pain monitoring and personalized opioid management. The project addresses limitations in patient-reported pain scales by deploying validated deep learning algorithms...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $834,899 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify inflammatory biosignatures that distinguish pain phenotypes in sickle cell disease. The research, titled "Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP)," develops proteomic signatures composed of multiple biomarkers to characterize...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.352 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single-molecule functional validation of neurogenomic alterations in opioid-exposed HIV brain tissue. The project performs single-molecule fiber-seq profiling on cingulate cortex tissue samples from the SCORCH (Single Cell Opioid Response in the Context of HIV) consortium, analyzing approximately...
- The National Center for Complementary and Integrative Health awarded the University of California, San Diego $788,967 on April 16, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to investigate the effects and mechanisms of psilocybin-induced pain relief in chronic phantom limb pain. The research will examine whether and how psilocybin modulates chronic phantom limb pain, a treatment-resistant condition affecting up to 64 percent of the...
- The National Institute on Drug Abuse awarded Albert Einstein College of Medicine $199,584 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a five-year mentored research and career development project establishing Dr. Michele Buonora as an independent clinician investigator in implementation science. The project conducts a hybrid type 1 effectiveness-implementation study examining patient-controlled analgesia (PCA) for acute pain management in...